Black Rock Inc. Nrx Pharmaceuticals, Inc. Transaction History

Black Rock Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.46 - $0.89 $38,885 - $75,234	-84,533 Reduced 22.53%	290,714 $139,000
Q1 2023 May 12, 2023	BUY	$0.66 - $1.4 $1,793 - $3,805	2,718 Added 0.73%	375,247 $247,000
Q4 2022 Feb 13, 2023	SELL	$0.79 - $9.19 $218,047 - $2.54 Million	-276,009 Reduced 42.56%	372,529 $413,000
Q3 2022 Nov 14, 2022	SELL	$0.2 - $8.07 $755 - $30,480	-3,777 Reduced 0.58%	648,538 $480,000
Q2 2022 Aug 12, 2022	BUY	$0.51 - $2.42 $64,679 - $306,909	126,822 Added 24.13%	652,315 $391,000
Q1 2022 May 12, 2022	BUY	$2.45 - $5.04 $24,610 - $50,626	10,045 Added 1.95%	525,493 $1.29 Million
Q4 2021 Feb 10, 2022	BUY	$4.5 - $11.91 $2.32 Million - $6.14 Million	515,448 New	515,448 $2.46 Million

17.4K

Ticker NRXP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,641,296
Market Cap $111M
Description
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-10...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.